Genmab and Seattle Genetics have collaborated to evaluate tisotumab vedotin in a Phase II clinical trial for the treatment of patients suffering from recurrent and/or metastatic cervical cancer.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Tisotumab vedotin comprises Genmab’s human antibody antibody that targets tissue factor (TF) along with Seattle Genetics’ antibody-drug conjugate (ADC) technology that includes a cleavable linker and cytotoxic drug, monomethyl auristatin E (MMAE).

The single arm, multi-centre Phase II trial is designed to enrol approximately 100 patients who relapsed or progressed following standard of care treatment with platinum containing chemotherapy and bevacizumab.

Planned to be initiated over the coming months, the results from the trial are expected to support a regulatory application for the approval of tisotumab vedotin.

“Standard therapies for previously treated recurrent and/or metastatic cervical cancer generally result in response rates of less than 15% and a median overall survival of six to eight months.”

Seattle Genetics president and CEO Clay Siegall said: “Standard therapies for previously treated recurrent and/or metastatic cervical cancer generally result in response rates of less than 15% and a median overall survival of six to eight months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Based on promising data from the Phase I/II clinical trial of tisotumab vedotin in recurrent and/or metastatic cervical cancer and feedback from the US Food and Drug Administration (FDA) on the planned trial, we and Genmab are advancing the programme into a potentially registrational study for these patients with high unmet medical need.”

The trial’s primary endpoint is overall response rate (ORR) as measured through independent review of RECIST v1.1 criteria, while the main secondary endpoints include duration of response (DoR) and safety.

Tisotumab vedotin is being further investigated in Phase I/II trials to treat solid tumours.

Image: Cervical adenocarcinoma. Photo: courtesy of Ed Uthman/Flickr.